
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The 2003 edition of the Red Book--a.k.a. the 2003 Report of the Committee on Infectious Diseases-26th Edition--is hot off the presses and available at the American Academy of Pediatrics (AAP) book store.






